Analysts Offer Insights on Healthcare Companies: Mainz Biomed B.V. (MYNZ), Xencor (XNCR) and Biotricity (BTCY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mainz Biomed B.V. (MYNZ – Research Report), Xencor (XNCR – Research Report) and Biotricity (BTCY – Research Report).

Mainz Biomed B.V. (MYNZ)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Mainz Biomed B.V. today and set a price target of $5.00. The company’s shares closed last Friday at $1.21, close to its 52-week low of $1.05.

According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -33.2% and a 21.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as OKYO Pharma Limited Sponsored ADR, Bausch + Lomb Corporation, and EyePoint Pharmaceuticals.

Mainz Biomed B.V. has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.

See the top stocks recommended by analysts >>

Xencor (XNCR)

In a report issued on November 15, Mara Goldstein from Mizuho Securities maintained a Buy rating on Xencor, with a price target of $59.00. The company’s shares closed last Friday at $19.22, close to its 52-week low of $16.49.

According to TipRanks.com, Goldstein is ranked 0 out of 5 stars with an average return of -8.3% and a 30.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

Currently, the analyst consensus on Xencor is a Strong Buy with an average price target of $38.75, representing a 106.4% upside. In a report issued on November 7, TD Cowen also maintained a Buy rating on the stock.

Biotricity (BTCY)

In a report released today, Kevin Dede from H.C. Wainwright downgraded Biotricity to Hold. The company’s shares closed last Friday at $0.99, close to its 52-week low of $0.70.

According to TipRanks.com, Dede is ranked 0 out of 5 stars with an average return of -8.8% and a 32.1% success rate. Dede covers the Technology sector, focusing on stocks such as WISeKey International Holding, AquaBounty Technologies, and BIT Mining.

The word on The Street in general, suggests a Hold analyst consensus rating for Biotricity.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MYNZ:

• Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
• Mainz Biomed reports Q3 EPS (39c), consensus (47c)
• Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
• Mainz Biomed to sell 4.17M shares at $1.20 in registered direct offering
• Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering